HilleVax, Inc. (HLVX) Research

HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.

Market snapshot

Symbol
HLVX
Price
$2.09
Day change
-0.48%
Market cap
$104.8M
P/E ratio
-2.31x
52-week range
1.34-2.17
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$32.00

Peer companies

  • Aadi Bioscience, Inc. (AADI)
  • Berkeley Lights, Inc. (BLI)
  • Cyteir Therapeutics, Inc. (CYT)
  • Decibel Therapeutics, Inc. (DBTX)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Jounce Therapeutics, Inc. (JNCE)
  • Miromatrix Medical Inc. (MIRO)
  • Opiant Pharmaceuticals, Inc. (OPNT)

Recent insider activity

  • TAKEDA PHARMACEUTICAL CO LTD — U-Tender (6724000 shares) on 2025-09-17
  • Frazier Life Sciences X, L.P. — U-Tender (17199 shares) on 2025-09-17
  • HERSHBERG ROBERT — U-Tender (1101498 shares) on 2025-09-17
  • Cocero Nanette — U-Tender (17199 shares) on 2025-09-17
  • HILLEMAN JERYL L — U-Tender (59224 shares) on 2025-09-17

Open HilleVax, Inc. (HLVX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.